Phio Pharmaceuticals
PHIO | NASDAQ
$0.75
-$0.02 (-2.72%)
At close: Nov 16, 2026, 4:00 PM ET
$0.77
+$0.02 (+2.80%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Phio Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| Robert J. Bitterman | President, Chief Executive Officer & Chairman |
| Jennifer Phillips | Senior Vice President of Regulatory & Corporate Affairs |
| Linda Mahoney | Senior Vice President of Development |
| Lisa Carson | CFO, Principal Accounting Officer and VP of Finance & Administration |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 13, 2026 | 8-K | Current Report |
| Sep 30, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 28, 2026 | S-8 | Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 25, 2026 | 4 | Filing |
| Sep 23, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
Phio Pharmaceuticals
| Country | United States |
| IPO Date | May 10, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Robert L. Bitterman |
Contact Details
411 Swedeland Road King of Prussia,
Pennsylvania 19406 United States
Stock Details
| Ticker Symbol | PHIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001533040 |
| CUSIP Number | 71880W501 |
| ISIN Number | US71880W5013 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove PHIO